NEW YORK, May 23 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) Inc's
VRX.TO Chief Executive Officer Joseph Papa said on Monday that
three weeks into the job, he sees there is a lot to work on at
the Canadian drugmaker but that he is encouraged by its pipeline
of new drugs.
Papa, speaking at the UBS Global Healthcare Conference, told
investors that he is focused on the drugmaker's new distribution
agreement with Walgreens Boots Alliance WBA.O , and sees
Valeant's problems with its previous pharmacy Philidor RX
Services as being "historical".